On 16 February 2006, orphan designation (EU/3/06/349) was granted by the European Commission to Vectura Group plc, United Kingdom, for apomorphine hydrochloride (inhalation use) for the treatment of off-periods in Parkinson's disease not responding to oral treatment.
The sponsorship was transferred to Vectura Ireland Limited, Ireland in March 2019.
EU/3/06/349: Public summary of positive opinion for orphan designation of apomorphine hydrochloride (inhalation use) for the treatment of off-periods in Parkinson’s disease not responding to oral treatment (PDF/130.36 KB)
First published: 24/08/2006
Last updated: 24/08/2006
Apomorphine hydrochloride (inhalation use)
|Disease / condition||
Treatment of off-periods in Parkinson's disease not responding to oral treatment
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;